Oncology Group

Latest stories

4d
9&10 News Cadillac
Munson Medical Center's Cowell Family Cancer Center: Treating the Patientbest care. "We are looking to treat the whole person, not just the particular
Munson Medical Center's Cowell Family Cancer Center: Treating the Patient
9&10 News Cadillac / Posted 4 days ago
best care. "We are looking to treat the whole person, not just the particular place in your body where you have cancer. Oncology group up here recognizes that a patient has emotional, mental and physical needs during cancer treatment and beyond,... Read more
12d
Business Wire
Opdivo® (nivolumab) Granted First Approval of a PD-1 Inhibitor in Hematology for the Treatment of Classical Hodgkin Lymphoma Patients Who Have Relapsed or Progressed After Auto-HSCT and Post-transplantation Brentuximab Vedotin by the FDA1was assessed by an independent radiographic review committee.1 Both studies ex
Opdivo® (nivolumab) Granted First Approval of a PD-1 Inhibitor in Hematology for the Treatment of Classical Hodgkin Lymphoma Patients Who Have Relapsed or Progressed After Auto-HSCT and Post-transplantation Brentuximab Vedotin by the FDA1
Business Wire / Posted 12 days ago
was assessed by an independent radiographic review committee.1 Both studies excluded patients with an Eastern Cooperative Oncology Group (ECOG) performance status of two or higher, autoimmune disease, symptomatic interstitial lung disease, hepatic... Read more
10 related stories
12d
Pleasanton Weekly
Celebration of Life event planned for June 7Dr. Kavitha P. Raj, a consultant at the Valley Medical Oncology group, will spe
Celebration of Life event planned for June 7
Pleasanton Weekly / Posted 12 days ago
Dr. Kavitha P. Raj, a consultant at the Valley Medical Oncology group, will speak on "Survivorship: Life after Cancer." Petra Lentz-Snow, a cancer survivor, will speak on "Journeys into Healing." A reception and registration will begin at 6:30 p.m.... Read more
20d
Business Wire
LUME-Meso trial enrols first patient: Boehringer Ingelheim’s new pivotal study investigating nintedanib for the treatment of malignant pleural mesotheliomaeligible to undergo surgical resection, have received no prior first-line thera
LUME-Meso trial enrols first patient: Boehringer Ingelheim’s new pivotal study investigating nintedanib for the treatment of malignant pleural mesothelioma
Business Wire / Posted 20 days ago
eligible to undergo surgical resection, have received no prior first-line therapies for MPM and hold an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. Lead investigator, Professor Giorgio V. Scagliotti, Chair of the Department... Read more

People in this news